Why I Kept My Cancer A Secret, And Why I Won t Anymore - NPR News wmfe.org - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from wmfe.org Daily Mail and Mail on Sunday newspapers.
Press release content from Globe Newswire. The AP news staff was not involved in its creation.
Veru Reports Strong Second-Quarter Financial Results Based on Record High FC2 Prescription Revenues
Veru Inc.May 12, 2021 GMT First Patient to Be Enrolled this Week in Phase 3 Clinical Trial of Sabizabulin
(VERU-111) in High Risk Hospitalized COVID-19 Patients New Drug Application Accepted for Review by FDA for Proprietary TADFIN Daily Oral Dosing Combination for BPH; PDUFA Date December 2021 Company Poised to Enroll First Patient in Phase 3 VERACITY Clinical Trial of Sabizabulin for Metastatic Castration and AR Targeting Agent Resistant Prostate Cancer Later this Month
(1)
GE Healthcare to scale Zionexa s FDA-approved PET imaging agent, Cerianna (fluoroestradiol F-18), used as an adjunct to biopsy for the detection of estrogen receptor (ER) positive lesions to help inform treatment selection for patients with recurrent or metastatic breast cancer
Aims to make Cerianna available to 75% of metastatic breast cancer patients in the U.S. by 2023
Acquisition demonstrates GE Healthcare s commitment to its precision health vision and builds additional pipeline of oncology and neurology tracers to help physicians personalize treatment
GE Healthcare today announced the acquisition of Zionexa, a leading innovator of in-vivo oncology and neurology biomarkers that help enable more personalized healthcare. The company aims to develop and bring to market Zionexa s pipeline biomarkers, as well as the recently FDA-approved PET imaging agent, Cerianna (fluoroestradiol F-18), which is used as an adjunct to biopsy for the detection of estrogen receptor (ER) posit
Share this article
Share this article
NEW YORK, April 26, 2021 /PRNewswire/ Pomerantz LLP announces that a class action lawsuit has been filed against Athenex, Inc. ( Athenex or the Company ) (NASDAQ: ATNX) and certain of its officers. The class action, filed in the United States District Court for the Western District of New York, and docketed under 21-cv-00413, is on behalf of a class consisting of all persons and entities other than Defendants that purchased or otherwise acquire Athenex common stock between August 7, 2019 and February 26, 2021, inclusive (the Class Period ). This action is brought on behalf of the Class for violations of Sections 10(b) and 20(a) of the Securities Exchange Act of 1934 (the Exchange Act ), 15 U.S.C. §§ 78j(b) and 78t(a) and Rule 10b-5 promulgated thereunder by the U.S. Securities and Exchange Commission, 17 C.F.R. § 240.10b-5.
SHAREHOLDER ALERT: Pomerantz Law Firm Reminds Shareholders with Losses on their Investment in Athenex, Inc., of Class Action Lawsuit and Upcoming Deadline – ATNX
04/24/2021 | 01:15am EDT
Send by mail :
Message :
Required fields
NEW YORK, April 24, 2021 (GLOBE NEWSWIRE) Pomerantz LLP announces that a class action lawsuit has been filed against Athenex, Inc. (“Athenex” or the “Company”) (NASDAQ: ATNX) and certain of its officers. The class action, filed in the United States District Court for the Western District of New York, and docketed under 21-cv-00413, is on behalf of a class consisting of all persons and entities other than Defendants that purchased or otherwise acquire Athenex common stock between August 7, 2019 and February 26, 2021, inclusive (the “Class Period”). This action is brought on behalf of the Class for violations of Sections 10(b) and 20(a) of the Securities Exchange Act of 1934 (the “Exchange Act”), 15 U.S.C. §§ 78j(b) and 78t(a)